Mesothelin-specific T cell responses have been observed in peripheral blood lymphocytes from patients with pancreatic cancer, including individuals who were administered a cancer vaccine candidate overexpressing mesothelin peptides and granulocyte-macrophage colony-stimulating factor [6, 13–15]. Here, MSLN is linked to familial pancreatic carcinoma.